Literature DB >> 30958566

A Tale of Two Complications of Obesity: NASH and Hepatocellular Carcinoma.

Renumathy Dhanasekaran1, Dean W Felsher2.   

Abstract

Entities:  

Year:  2019        PMID： 30958566      PMCID： PMC6717523          DOI： 10.1002/hep.30649

Source DB:  PubMed          Journal:  Hepatology        ISSN： 0270-9139            Impact factor:   17.425


× No keyword cloud information.
  8 in total

1.  Hepatic oxidative stress promotes insulin-STAT-5 signaling and obesity by inactivating protein tyrosine phosphatase N2.

Authors:  Esteban N Gurzov; Melanie Tran; Manuel A Fernandez-Rojo; Troy L Merry; Xinmei Zhang; Yang Xu; Atsushi Fukushima; Michael J Waters; Matthew J Watt; Sofianos Andrikopoulos; Benjamin G Neel; Tony Tiganis
Journal:  Cell Metab       Date:  2014-06-19       Impact factor: 27.287

2.  Systematic review with meta-analysis: risk of hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis compared to other liver diseases.

Authors:  Jonathan G Stine; Brian J Wentworth; Alex Zimmet; Mary E Rinella; Rohit Loomba; Stephen H Caldwell; Curtis K Argo
Journal:  Aliment Pharmacol Ther       Date:  2018-08-22       Impact factor: 8.171

Review 3.  Should we undertake surveillance for HCC in patients with NAFLD?

Authors:  Ramy Younes; Elisabetta Bugianesi
Journal:  J Hepatol       Date:  2017-11-06       Impact factor: 25.083

4.  Opposing roles of STAT1 and STAT3 in T cell-mediated hepatitis: regulation by SOCS.

Authors:  Feng Hong; Barbara Jaruga; Won Ho Kim; Svetlana Radaeva; Osama N El-Assal; Zhigang Tian; Van-Anh Nguyen; Bin Gao
Journal:  J Clin Invest       Date:  2002-11       Impact factor: 14.808

5.  Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis.

Authors:  Valérie Paradis; Stéphane Zalinski; Emna Chelbi; Nathalie Guedj; Françoise Degos; Valérie Vilgrain; Pierre Bedossa; Jacques Belghiti
Journal:  Hepatology       Date:  2009-03       Impact factor: 17.425

6.  STAT3 is a master regulator of epithelial identity and KRAS-driven tumorigenesis.

Authors:  Stephen D'Amico; Jiaqi Shi; Benjamin L Martin; Howard C Crawford; Oleksi Petrenko; Nancy C Reich
Journal:  Genes Dev       Date:  2018-08-22       Impact factor: 11.361

7.  Obesity Drives STAT-1-Dependent NASH and STAT-3-Dependent HCC.

Authors:  Marcus Grohmann; Florian Wiede; Garron T Dodd; Esteban N Gurzov; Geraldine J Ooi; Tariq Butt; Aliki A Rasmiena; Supreet Kaur; Twishi Gulati; Pei K Goh; Aislinn E Treloar; Stuart Archer; Wendy A Brown; Mathias Muller; Matthew J Watt; Osamu Ohara; Catriona A McLean; Tony Tiganis
Journal:  Cell       Date:  2018-10-25       Impact factor: 41.582

Review 8.  Weighing the benefits of hepatocellular carcinoma surveillance against potential harms.

Authors:  Daniel Geh; Fahd A Rana; Helen L Reeves
Journal:  J Hepatocell Carcinoma       Date:  2019-01-14
  8 in total
  8 in total

1.  MicroRNA-21 Plays Multiple Oncometabolic Roles in the Process of NAFLD-Related Hepatocellular Carcinoma via PI3K/AKT, TGF-β, and STAT3 Signaling.

Authors:  Chi-Yu Lai; Kun-Yun Yeh; Chiu-Ya Lin; Yang-Wen Hsieh; Hsin-Hung Lai; Jim-Ray Chen; Chia-Chun Hsu; Guor Mour Her
Journal:  Cancers (Basel)       Date:  2021-02-24       Impact factor: 6.639

2.  GDI2 is a novel diagnostic and prognostic biomarker in hepatocellular carcinoma.

Authors:  Wen Zhang; Zhongjian Liu; Shilin Xia; Lei Yao; Lan Li; Ziying Gan; Hui Tang; Qiang Guo; Xinmin Yan; Zhiwei Sun
Journal:  Aging (Albany NY)       Date:  2021-12-11       Impact factor: 5.682

3.  Morbidity, Prognostic Factors, and Competing Risk Nomogram for Combined Hepatocellular-Cholangiocarcinoma.

Authors:  Xiaoyuan Chen; Yiwei Lu; Xiaoli Shi; Xuejiao Chen; Dawei Rong; Guoyong Han; Long Zhang; Chuangye Ni; Jie Zhao; Yun Gao; Xuehao Wang
Journal:  J Oncol       Date:  2021-12-10       Impact factor: 4.375

4.  Integrative lipidomic and transcriptomic study unravels the therapeutic effects of saikosaponins A and D on non-alcoholic fatty liver disease.

Authors:  Xiaojiaoyang Li; Junde Ge; Yajing Li; Yajie Cai; Qi Zheng; Nana Huang; Yiqing Gu; Qi Han; Yunqian Li; Rong Sun; Runping Liu
Journal:  Acta Pharm Sin B       Date:  2021-03-11       Impact factor: 11.413

5.  Targeted Inhibition of LPL/FABP4/CPT1 fatty acid metabolic axis can effectively prevent the progression of nonalcoholic steatohepatitis to liver cancer.

Authors:  Haoran Yang; Qingmei Deng; Tun Ni; Yu Liu; Li Lu; Haiming Dai; Hongzhi Wang; Wulin Yang
Journal:  Int J Biol Sci       Date:  2021-10-11       Impact factor: 6.580

6.  Mir-454-3p induced WTX deficiency promotes hepatocellular carcinoma progressions through regulating TGF-β signaling pathway.

Authors:  Hui Liu; Juan Zheng; Shengqian Yang; Qibei Zong; Zhiwen Wang; Xinghua Liao
Journal:  J Cancer       Date:  2022-03-21       Impact factor: 4.207

7.  Outcome after Resection for Hepatocellular Carcinoma in Noncirrhotic Liver-A Single Centre Study.

Authors:  Lea Penzkofer; Jens Mittler; Stefan Heinrich; Nicolas Wachter; Beate K Straub; Roman Kloeckner; Fabian Stoehr; Simon Johannes Gairing; Fabian Bartsch; Hauke Lang
Journal:  J Clin Med       Date:  2022-09-30       Impact factor: 4.964

Review 8.  Cancer and hepatic steatosis.

Authors:  R Paternostro; W Sieghart; M Trauner; M Pinter
Journal:  ESMO Open       Date:  2021-06-14
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.